Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 6/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10331877 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HTR6CYP4F2CYP4A11KDM1A | |
| SCHEMBL7355324 | 0.83 | MTNR1A (0.48) | HTR6MTNR1A | |
| SCHEMBL2027583 | 0.80 | ALDH1A1 (0.54) | ALDH1A1CYP4F2CYP4A11KDM1A | |
| SCHEMBL13092162 | 0.79 | ADRA2A (0.53) | ALDH1A1HTR6ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL784724 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM1A | |
| SCHEMBL29653974 | 0.78 | ALDH1A1 (0.56) | ALDH1A1CYP4F2CYP4A11KDM1A | |
| SCHEMBL8370378 | 0.77 | ALDH1A1 (0.54) | ALDH1A1CYP4F2CYP4A11KDM1A | |
| SCHEMBL15235463 | 0.77 | ALDH1A1 (0.54) | ALDH1A1CYP4F2CYP4A11KDM1A | |
| Oxalic Acid SCHEMBL5361082 | 0.76 | HTR6 (0.56) | ALDH1A1HTR6KDM4C | |
| SCHEMBL15839921 | 0.75 | HTR6 (0.54) | HTR6KDM1AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8663629-B2 | Kallikrein-binding “kunitz domain” proteins and analogues thereof | DYAX CORP. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120328517-A1 | KALLIKREIN-BINDING \"KUNITZ DOMAIN\" PROTEINS AND ANALOGUES THEREOF | DYAX CORP. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8283321-B2 | Kallikrein-binding “Kunitz domain” proteins and analogues thereof | DYAX CORP. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20110136746-A1 | Kallikrein-Binding \"Kunitz Domain\" Proteins and Analogues Thereof | DYAX CORP. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7628983-B2 | Kallikrein-binding “Kunitz domain” proteins and analogues thereof | DYAX CORP. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060264603-A1 | Kallikrein-binding \"Kunitz domain\" proteins and analogues thereof | DYAX CORP | 2006-11-23 | — | — | US | disclosed |
| US-20040009905-A1 | Template associated NPY Y2-receptor agonists | B.M.R.A. CORPORATION B.V. | 2004-01-15 | — | — | US | disclosed |
| US-6288029-B1 | TEMPLATE ASSEMBLED SYNTHETIC PEPTIDE EFFECTIVE TO TREAT RESPIRATORY SYSTEM DISORDERS | MUTTER MANFRED (CH) | 2001-09-11 | — | — | US | disclosed |
| EP-1068221-A2 | TEMPLATE ASSOCIATED NPY Y2-RECEPTOR AGONISTS | B.M.R.A. CORPORATION B.V. (NL) | 2001-01-17 | — | — | EP | disclosed |
| US-6017879-A | Template associated NPY Y2-receptor agonists | B.M.R.A. CORPORATION B.V. (NL) | 2000-01-25 | — | — | US | disclosed |
| WO-1999051626-A2 | TEMPLATE ASSOCIATED NPY Y2-RECEPTOR AGONISTS | B.M.R.A. CORP. B.V. (NL) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328517-A1 | KALLIKREIN-BINDING \"KUNITZ DOMAIN\" PROTEINS AND ANALOGUES THEREOF | KLKB1, KLK2, KLK1 | ALDH1A1 4855/4885HTR6 4364/4885CYP4F2 2781/4885 |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | DNPEP, IAPP, VIP | ALDH1A1 4687/4885HTR6 3879/4885CYP4F2 4508/4885 |
| US-20060264603-A1 | Kallikrein-binding \"Kunitz domain\" proteins and analogues thereof | KLKB1, KLK2, KLK1 | ALDH1A1 4855/4885HTR6 4364/4885CYP4F2 2781/4885 |
| US-20040009905-A1 | Template associated NPY Y2-receptor agonists | NPY1R, NPY2R, NPY4R | ALDH1A1 4870/4885HTR6 307/4885CYP4F2 2181/4885 |
| US-20110136746-A1 | Kallikrein-Binding \"Kunitz Domain\" Proteins and Analogues Thereof | KLKB1, KLK2, KLK1 | ALDH1A1 4855/4885HTR6 4364/4885CYP4F2 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.